Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetes.

ABSTRACT:

Introduction

A new formulation of exenatide has become available recently that is the first antidiabetic medication for type 2 diabetes mellitus (T2DM) dosed on a weekly schedule. This review summarizes the pharmacology, efficacy, and safety of exenatide once weekly (exenatide QW). The results are interpreted in terms of the pathophysiology of T2DM, as well as the pharmacology of the new formulation.

Methods

Relevant literature on exenatide QW and diabetes was identified through PubMed database searches from inception until September 2013.

Discussion

In the new once-weekly formulation of exenatide, the exenatide molecule is dispersed in microspheres. Following subcutaneous injection, these microspheres degrade in situ and slowly release active agent. In clinical trial

SUBMITTER: Grossman SS 

PROVIDER: S-EPMC3961598 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature